The blockbuster diabetes drug Ozempic, a semaglutide injection made by Novo Nordisk, has become a household name on both sides of the Atlantic. Yet a peculiar divergence has emerged: Canadians can now access a generic version, while Americans remain trapped in a system that prioritises patent protection over patient access. This development is more than a simple regulatory glitch. It is a case study in how different nations balance intellectual property, public health, and market incentives.
In Canada, the Patented Medicines Prices Review Board and Health Canada moved decisively. In 2023, the board allowed a generic manufacturer, Apotex, to launch a lower-cost version after a nuanced interpretation of patent law. The key was a 'licence of right' provision that permits third-party production when a drug is deemed to have insufficient supply or excessive pricing. Canada’s single-payer system meant the government could negotiate directly with Apotex, ensuring availability at roughly 40% less than the brand-name price.
The United States, by contrast, remains mired in a labyrinth of intellectual property. The Hatch-Waxman Act, designed to balance innovation and competition, has become a tool for brand-name companies to extend monopolies through 'patent thickets'. Novo Nordisk holds over a dozen patents on Ozempic, covering not just the molecule but the delivery device, formulation, and even methods of use. These secondary patents can last years beyond the original 20-year term, creating a wall that generic manufacturers must climb.
Further complicating matters is the US system of rebates and middlemen. Pharmacy benefit managers (PBMs) often negotiate rebates from brand-name manufacturers, which are larger for patented drugs. A generic would eliminate those rebates, potentially reducing PBM profits. This perverse incentive means the market itself resists competition. The US also lacks Canada’s federal price negotiation. Medicare, which covers many diabetic patients, is legally barred from bargaining over drug prices under the 'non-interference clause' passed in 2003.
The result is a stark disparity. A month’s supply of Ozempic in Canada costs around CAD 300 (USD 220). In the US, the same drug can run USD 900 to 1,200 without insurance. Americans with private insurance often pay high co-pays, while uninsured patients face the full brunt. The Biden administration’s Inflation Reduction Act attempted to address this by allowing Medicare to negotiate prices for a limited set of drugs, but Ozempic is not scheduled for negotiation until 2027 at the earliest.
The implications extend beyond cost. Access to affordable medication influences adherence. Studies show that high co-pays lead patients to skip doses, worsening health outcomes and increasing long-term costs. In a classic 'Black Mirror' twist, our algorithmic healthcare system optimises for profit, not wellness. The very algorithms used by insurers to set premiums and co-pays create a feedback loop where the sick are priced out of care.
But there is hope. The Federal Trade Commission has recently scrutinised PBM practices, and several states are considering laws to ban 'pay-for-delay' deals that keep generics off the market. Yet without a fundamental shift in how patents are granted and defended, the US will remain a laggard. Canada’s approach offers a blueprint: a willingness to prioritise public health over intellectual property absolutism. It is time for Silicon Valley’s ethos of 'move fast and break things' to be applied to healthcare, breaking the patents that keep people sick and poor. The future we choose will depend on whether we value algorithms or outcomes.
